BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 3, 2023
Distillery Therapeutics

Blocking OGG1 for pulmonary fibrosis

BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining
BioCentury | Dec 4, 2018
Distillery Therapeutics

Inflammation

BioCentury | Nov 16, 2018
Preclinical News

Preventing DNA repair blocks inflammation

BioCentury | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

An analysis of emerging targets at ASH by mechanism
BioCentury | Apr 11, 2011
Clinical News

Tarceva erlotinib: Additional Phase II data

Items per page:
1 - 6 of 6